XsunX, Inc. has developed and begun to market a hybrid manufacturing solution to produce high performance Copper Indium Gallium di Selenide CIGS thin film solar cells. Our patent pending deposition system and thermal evaporation processing technology, which we call CIGSolar TM , focuses on the mass production of individual thin film CIGS solar cells that match silicon solar cell dimensions and can be offered as a high efficiency, capital efficient, lowest cost alternative to the use of silicon solar cells. lt br / gt lt br / gt We are offering licenses for the use of the CIGSolar TM process technology through which we will generate revenue on equipment, licensing fees, and long term manufacturing royalty revenues. lt br / gt lt br / gt Our thin film CIGSolar TM cells are the first solar cell technology to target an existing multi billion dollar silicon solar cell supply chain as a less costly alternative. The CIGSolar TM solution offers the potential to revolutionize the solar industry offering the highest yield CIGS manufacturing technology available in the market today. lt br / gt lt br / gt XsunX Technology Advantage lt br / gt lt br / gt The US National Renewable Energy Laboratories NREL recently certified peak conversion efficiency of . with an overall average of . for XsunX CIGSolar TM samples. The key to delivering this potential is an innovative new approach that bridges the gap between inexpensive thin film and high efficiency silicon wafer technologies to produce a new breed of solar cells combining the best attributes of each technology.
Quote | Xsunx Inc (OTCMKTS:XSNX)
Last: | $0.007 |
---|---|
Change Percent: | 14.29% |
Open: | $0.0066 |
Close: | $0.007 |
High: | $0.008545 |
Low: | $0.0066 |
Volume: | 639,176 |
Last Trade Date Time: | 04/22/2024 03:00:00 am |
News | Xsunx Inc (OTCMKTS:XSNX)
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7 million finan...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Message Board Posts | Xsunx Inc (OTCMKTS:XSNX)
Subject | By | Source | When |
---|---|---|---|
Looks good today on low vol, watching | InvestorNews1 | investorshub | 02/15/2023 8:25:32 PM |
Unfortunately... | splintered sunlight | investorshub | 01/26/2023 4:52:23 PM |
Looks like $XSNX is owning up to owing | BooDog | investorshub | 01/26/2023 4:09:49 PM |
What do you make of this? | splintered sunlight | investorshub | 01/24/2023 2:17:48 PM |
8K yesterday..... | splintered sunlight | investorshub | 01/24/2023 1:53:03 PM |
News, Short Squeeze, Breakout and More Instantly...
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7 million finan...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...